Search results
Results From The WOW.Com Content Network
COVID-19. Pfizer. 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine. HIV. non- nucleoside reverse transcriptase inhibitor. Nitazoxanide. Broad-spectrum antiviral.
Antiretroviral drugs for HIV. Antiviral drugs are a class of medication used for treating viral infections. [1] Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. [2] Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic (also termed ...
Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. [ 5 ] Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. [ 6 ]
In May 2022, Pfizer suggested repeating the treatment, but the FDA said there was no evidence of benefit. [38] [39] In June 2022, a US case report of ten people with rebound COVID‑19 had found viral load during relapse was comparable to levels during an initial infection, and high enough to cause secondary transmission. [40]
Here’s what to know. Hanh Truong. If you recently tested positive for COVID-19, you may be eligible for antiviral treatments to help reduce your infection. Earlier this year, when the omicron ...
Streptococcal pharyngitis, also known as streptococcal sore throat ( strep throat ), is pharyngitis (an infection of the pharynx, the back of the throat) caused by Streptococcus pyogenes, a gram-positive, group A streptococcus. [10] [11] Common symptoms include fever, sore throat, red tonsils, and enlarged lymph nodes in the front of the neck.
In the United States, remdesivir is indicated for the treatment of COVID‑19 in people 28 days of age and older and weighing at least 3 kilograms (6.6 lb) who are hospitalized; or not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death.
Protease inhibitors were the second class of antiretroviral drugs developed. The first members of this class, saquinavir, ritonavir, and indinavir, were approved in late 1995–1996. Within 2 years, annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000 [ 5] Prior to this the annual death rate had been ...